Agile Therapeutics, Inc. provided revenue guidance for the First quarter 2023. For the period, the Company expects net revenue is expected to be in the range of $3.8 to $4.0 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3777 USD | -0.48% | +0.72% | -80.63% |
May. 15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
1st Jan change | Capi. | |
---|---|---|
-80.63% | 2.6M | |
+7.68% | 113B | |
+10.96% | 106B | |
+0.41% | 22.27B | |
-11.83% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.83% | 17.24B | |
+6.97% | 14.29B | |
+35.14% | 12.52B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the First Quarter 2023